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Introduction: Ophthalmia neonatorum is a severe, sight-threatening condition that occurs in 
neonates worldwide. Etiological factors include chemical agents, viruses, and bacteria, such as 
Neisseria gonorrhoeae and Chlamydia trachomatis acquired from infected mothers at birth. 
Prevalence varies geographically, depending upon socioeconomic conditions, maternal health 
care, and prophylactic treatments available. Antibiotic resistance, particularly in N. gonorrhoeae, 
is a major challenge in treating ophthalmia neonatorum.  
Areas covered: This review explores the epidemiology and diagnosis of ophthalmia neonatorum 
and analyses the history and practices of prophylaxis and treatment. In this context, the 
challenges in treating ophthalmia neonatorum today are discussed and innovations that may 
overcome these challenges in the future are presented. Advantages and challenges of strategies 
to prevent ophthalmia neonatorum involving prophylaxis of infants and those using screening 
and treatment of mothers are explored. 
Expert commentary: Despite the potential to rapidly cause blindness, there are no universal 
guidelines for the prevention and treatment of ophthalmia neonatorum. Due to the increasing 
number of treatment failures, particularly those of extensively drug-resistant N. gonorrhoeae, a 
pragmatic approach is needed. Enhanced availability of screening and treatment of pregnant 
mothers, coupled with development of new antimicrobial ocular prophylaxis and treatments, 
provide options for a variety of settings.  
Key words: Antibiotic resistance, neonatal conjunctivitis, Chlamydia trachomatis, gonococcal 




Ophthalmia neonatorum, also called neonatal conjunctivitis, is a term for all forms of 
conjunctival inflammation that occurs in neonates within the first month of birth [1-2]. The 
conjunctiva lines both the sclera (the white outer surface of the eye) and the inside of the eyelids, 
as the bulbar conjunctiva and the palpebral conjunctiva, respectively [3-4]. Both of these 
conjunctival surfaces that touch one another, are involved in ophthalmia neonatorum. The 
etiological agents of ophthalmia neonatorum include sexually transmitted bacteria, non-sexually 
transmitted bacteria, viruses, and chemical toxicity from substances such as silver nitrate [5-6]. 
Clinical manifestations of ophthalmia neonatorum include purulent discharge and redness and 
swelling of the eyelid and conjunctiva [7-9]. In severe cases, the cornea may become affected, 
resulting in inflammation, thinning, ulceration, perforation, and ultimately blindness [10]. 
Chemical conjunctivitis usually resolves within 2 days [10-11] and may not usually require 
treatment [11], while those of infectious origin often require treatment [12-13]. 
Ophthalmia neonatorum is described as an ocular emergency [14] because of the 
potential to not only cause blindness but, depending on the infectious organism, its sequelae 
can also extend to other parts of the body causing infections that can be potentially fatal, 
depending on the infecting organism [10,15]. 
1.1 Sexually transmitted infections that cause ophthalmia neonatorum 
Chlamydia trachomatis and Neisseria gonorrhoeae are the main sexually transmitted bacteria that 
cause 2% to 40% and under 1% of ophthalmia neonatorum cases, respectively, whilst sexually 
transmitted viruses like herpes simplex virus cause under 1% of cases [5].  Sexually transmitted 
infections of the mother are transferred to the eyes of the infant during passage through the birth 
canal. In addition, there have been reports of intrauterine as well as transplacental or 
transmembrane infection in cases of caesarean section [16]. 
1.2 Non-sexually transmitted infections that cause ophthalmia neonatorum 
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Non-sexually transmitted infections that cause ophthalmia neonatorum include those 
caused by Streptococcus pneumoniae, Streptococcus viridans, Staphylococcus aureus, Pseudomonas 
aeruginosa, Haemophilus influenzae, Escherichia coli, Moraxella catarrhalis, and Klebsiella 
pneumoniae, being responsible together for about 30% - 50% of cases, with adenovirus 
implicated in about 1% of cases [5,15,17-19]. Some of these species linked with ophthalmia 
neonatorum, such as S. aureus and P. aeruginosa, may be acquired within hospital neonatal wards 
or intensive care units [20]. Whilst several studies have identified S. aureus or Staphylococcus 
epidermidis as causative agents of ophthalmia neonatorum [8,19-23], the occurrence of the 
bacteria on the conjunctiva and as a skin flora surrounding the areas of the eyes have raised 
questions regarding their involvement as etiologic agents of ophthalmia neonatorum [6,19,23].   
1.3 History, epidemiology, and burden of disease 
1.3.1 Ophthalmia neonatorum before antibiotics 
In the pre-antibiotic era, the burden of ophthalmia neonatorum disease was readily 
apparent, with large numbers of infants losing their eyesight at birth. For example, in 1880, 
ophthalmia neonatorum was responsible for 79% of the cases of blindness in children in 
institutions for the blind [24]. In the United States between 1906 and 1911, 24% of new 
admissions to schools for the blind were due to ophthalmia neonatorum [25]. A new hospital was 
opened in 1918, in London, to specifically treat infants with ophthalmia neonatorum, due to the 
high number of cases and the need for prompt treatment in an attempt to prevent ocular 
perforation and blindness [26-27]. This was one of two hospitals arranged to be provided in 
London at the time and followed examples set in Liverpool, Glasgow, and Manchester [26-27]. A 
major breakthrough in the prevention of ophthalmia neonatorum came with the introduction of 
Credé’s silver nitrate prophylaxis, first introduced in 1881 [28], which reduced the cases of 
ophthalmia neonatorum due to infection, although it was not without some chemical 
conjunctivitis and toxicity [6,29-30]. This will be discussed in detail in section 1.5.1. 
1.3.2 Ophthalmia neonatorum prevalence today 
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Ophthalmia neonatorum remains a global issue, threatening the sight of children 
worldwide [31-32]. The prevalence of ophthalmia neonatorum varies for different regions of the 
world and due to underreporting, decades of relatively low rates of ophthalmia neonatorum 
associated blindness in developed regions, and lack of resources for either diagnostics or 
treatment in low resource areas, there are few recent figures available and those that are 
available are specific to a particular etiological agent [5-6,8-9,18-24]. 
Ophthalmia neonatorum is listed amongst the World Health Organization (WHO) priority 
eye diseases as a major cause of childhood blindness in low-income countries [33]. The burden 
of childhood blindness affects the quality of life, productivity of the child, and impacts 
socioeconomically on the family as well as the wider society [34-35]. Ophthalmia neonatorum 
remains one of the major reasons for blindness in low-income countries [33,36]. The rate of visual 
impairment or blindness attributable to ophthalmia neonatorum have been reported to be 
between 0.4% and 5.9% in parts of Asia [34,37-41] and Africa [37,42-46] as shown in Figure 1. 
The incidence of ophthalmia neonatorum has been closely linked to the burden of sexually 
transmitted infections (STIs) in a population, particularly the maternal population [47-48]. Of the 
STIs causing ophthalmia neonatorum, C. trachomatis is the most common etiology, however N. 
gonorrhoeae causes more severe complications that can progress to blindness within 24 hours 
[49-50]. Although chlamydial ophthalmia neonatorum does not rapidly progress and directly 
compromise the integrity of the eye via perforation like gonococcal infection, chlamydial sequelae 
may result in conjunctival scarring and infiltration of the cornea by abnormal vessels and fibrous 
tissue also known as micropannus [51-52]. A conservative estimation reveals that over 50% of 
women with N. gonorrhoeae and C. trachomatis infection are asymptomatic and so are unaware 
of the infection [53-55]. 
In developed countries, C. trachomatis is the most common infectious agent causing 
ophthalmia neonatorum, accounting for 2-40% of cases, compared to less than 1% caused by N. 
gonorrhoeae [5,56-57]. The prevalence rate of gonococcal and chlamydial ophthalmia 
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neonatorum is reported as 3.7 per 100,000 and 6.9 per 100,000 live births, respectively, in the 
United Kingdom [58]. However, a study of hospital data in England from 2000-2011 showed 
marked fluctuations in annual figures and underestimations, suggesting that the rate may be 
much higher [59].  In the United States, prevalence rates of chlamydial and gonococcal 
conjunctivitis in 2015 were 2.1 and 0.2 cases per 100,000 live births, however this is also 
predicted to be an underestimate [60]. In a surveillance study by Kreisel et al. [60] using isolates 
sent to the Centers for Disease Control and Prevention (CDC), it was noted that 85% of potential 
ophthalmia neonatorum cases were excluded because the specimen source for the gonococcal or 
chlamydial isolates in patients less than one year-old was not indicated as “eye” or “conjunctiva”, 
with 52% having an “unknown”, “other-not specified”, or “missing” specimen source. In New 
Zealand, the prevalence rate for chlamydial ophthalmia neonatorum from 2013-2016 was 145.9 
per 100,000 live births and for gonococcal ophthalmia neonatorum 3.79 per 100,000 live births 
[61]. 
It is estimated that 20-75% and 15-35% of ophthalmia neonatorum cases in developing 
countries that present to the hospital are attributable to N. gonorrhoeae and C. trachomatis, 
respectively [31].  C. trachomatis accounts for 1.8% to 33% of ophthalmia neonatorum cases in 
hospitals in Africa [7,62-66] and 12.5% - 60% in hospitals in Asia [67-69]. It should be noted that 
in some investigations no C. trachomatis are identified. This is due to regional differences in 
practice, influenced by the availability of diagnostic facilities and resources in different healthcare 
settings. Even where possible and best practice, it is sometimes not routine; 85% of surveyed 
global members of the American Association of Paediatric Ophthalmology and Strabismus stated 
that they treat ophthalmia neonatorum empirically within the first 10 days of life and 75% do so 
thereafter [87]. Culture for diagnostic growth of C. trachomatis is often not used, due to the 
requirement to culture on eukaryotic cell monolayers, however identification of the bacteria by 
this method is possible when facilities are available [19, 70]. Nucleic acid amplification tests 
(NAATs) are often considered superior for identification of urogenital infections of C. trachomatis 
[70]; for ocular infections, NAATs are recommended by the WHO [92], but not by the US Food and 
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Drug Administration (FDA), which instead recommends direct fluorescence antibody (DFA) 
assays for chlamydial ophthalmia neonatorum diagnostics [93]. Testing for C. trachomatis can 
also be achieved via cytological examination from smears taken from the infant’s eyes [58,70]. 
This Giemsa staining method can have up to 90% sensitivity in diagnosing acute inclusion 
conjunctivitis in newborns, however molecular detection methods using PCR have greater 
sensitivity [58,70]. 
Cases of gonococcal ophthalmia neonatorum vary by region; a hospital in Singapore, for 
example reported 68% of cases between 1983 and 1986 were caused by N. gonorrhoeae [71]. 
Infection of the same patient with both N. gonorrhoeae and C. trachomatis, a coinfection causing 
ophthalmia neonatorum, has been reported with a rate estimated at 3% [63,69]. 
With the decline in gonorrhoea sexually transmitted infections in industrialized countries 
in the 1970’s and early 1980’s, there was a decline in ophthalmia neonatorum caused by N. 
gonorrhoeae [24,47], however the same was not observed for C. trachomatis [47]. Also, some 
developed countries instituted prenatal screening of pregnant women for sexually transmitted 
infections [24]. These circumstances reduced the incidence of ophthalmia neonatorum in many 
developed countries. However, this dynamic changed due to changes in STI prevalence and 
antimicrobial resistance.  There was a substantial rise in the diagnoses of N. gonorrhoeae 
infections in England from 14,985 in 2008 to 56,259 in 2018 [72]. Gonorrhoea diagnoses in the 
United States have also risen, climbing from a historic low in 2009 up 75.2% to 555,608 in 2017 
[73]. There were 87 million cases of gonorrhoea STI estimated by the WHO in 2016 and 
increasingly fewer options for effective antibiotic treatment of many isolates [74-78]. Also, 
factors such as demographic, social, and legal barriers may restrict access to needed infection 
control measures [74]. The case reported of a multi-drug resistant strain of N. gonorrhoeae in the 
UK of a heterosexual man who had sexual contact with a female partner in South East Asia 
explains the role of migration and sex tourism in increasing the risk of sexually transmitted 
infection in the general population, having been acquired from a high-risk population [74-75]. 
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The Western Pacific region, where this extensively resistant strain originated, has been reporting 
widespread high level resistance to penicillin and ciprofloxacin and increased minimum 
inhibitory concentration (MIC) values for ceftriaxone, as well as ceftriaxone resistance, for several 
years from its 37 countries including developed countries like Japan, Australia, and developing 
countries such as Vietnam, Malaysia, and the Philippines [79]. 
On the other hand, non-sexually transmitted bacteria have been reported to cause 
ophthalmia neonatorum, including Staphylococcus aureus, Staphylococcus epidermidis, 
Staphylococcus saprophyticus, Haemophilus influenzae, Escherichia coli, Streptococcus viridans, 
Streptococcus pneumoniae, Klebsiella pneumonia, and Pseudomonas aeruginosa [8,19,22-23,80-
81]. Although there is concern about whether S. aureus is the cause of ophthalmia neonatorum, 
given its presence as normal flora and presence from swab in healthy infants, it has a reported 
prevalence of 51.5% in Norway [22], 27.6% in Argentina [80], 31% in Iran [23], 36% in Hong 
Kong [81], 17.8% in southern China [19], and 65% in Pakistan [8]. 
1.4 Investigation of ophthalmia neonatorum 
Presented with an infant with a suspected case of ophthalmia neonatorum, ocular 
specimens are obtained and investigated to identify the etiological agent, using various culture 
and non-culture tests, depending upon the facilities available and current practice in the 
healthcare setting. In some cases paediatricians and eyecare specialists treat without microbial 
identification; if the symptoms clear, no further investigation is undertaken [87]. Investigations 
in some clinical settings may involve laboratory cultures and microscopy, including Gram staining 
from conjunctival swabs and Giemsa staining of epithelial cells scraped from conjunctivae in cases 
of suspected chlamydial ophthalmia neonatorum to determine the etiologic agent [7-
8,17,23,5870,82-83,92-93]. Gram stain results revealing Gram-negative diplococci in conjunctival 
exudate can rapidly give a strongly presumptive diagnosis of gonococcal ophthalmia neonatorum 
[7-8,17,82-83,91-92]. In healthcare settings with facilities and resources to do so, the standard 
may be to conduct non-culture tests such as NAATs, which amplify sequences specific to N. 
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gonorrhoeae and C. trachomatis [70,91-92]. Despite the greater sensitivity and specificity of 
NAATs compared to culture, the FDA does not recommend it for identification of gonococcal or 
chlamydia conjunctival infections [92-93]. Less commonly used enzyme immunoassays (EIA) can 
also identify gonococcal or chlamydial antigens [70,82-83,91-93]. Molecular tests, including 
NAATs, exhibit greater sensitivity, can detect non-viable organisms improving specimen 
collection and storage, offer the option of clinician or self-collected swabs, and can be non-
invasive, however when culture-based testing is available, it is particularly useful because it can 
be applied to a variety of specimen sources, including ocular, and culture-based methods are able 
to detect antimicrobial resistance, which is an important consideration in gonococcal ophthalmia 
neonatorum [6,12,58,70,82,91-92]. 
The greater sensitivity of NAATs may lead to false positive results such as was observed 
in studies where NAAT positive cases of gonococcal infection exhibited a corresponding culture 
negative result for the same cases [84]. For ophthalmia neonatorum, the opposite may also be the 
case, where NAATs results are negative when N. gonorrhoeae are present. A comparison of three 
commercial NAATs kits showed variability in results dependent upon sample site location, with 
eye swabs giving the worst results, confirming known positive cases from only 54.5% of samples 
[85]. Although the CDC and Public Health England (PHE) do not recommend using less sensitive 
non-NAAT tests (including culture test) to confirm positive results of highly sensitive tests like 
NAAT, the additional use of culture tests for isolation of microbial strains and antimicrobial 
resistance testing [70,82] and perhaps as follow-up testing [84-85], including proof of cure testing 
in cases of STI, may be beneficial. 
Laboratory test results are often available within 24 to 72 hours, depending on the type 
of test used and diagnostic facilities available [70,82]. This is a concern when managing potential 
gonococcal ophthalmia neonatorum, which can cause severe damage to the cornea and rapidly 
cause permanent visual impairment, including blindness within 24 hours [24,49-50]. Hence, 
there may be the need to start treatment while laboratory test results are being awaited.  
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1.5 Management of ophthalmia neonatorum 
The management of ophthalmia neonatorum involves the implementation of various 
strategies aimed at prevention and at treatment following development of symptoms.  
Preventative approaches involve administration of eye prophylaxis at birth [6,24-25,28-
30,32,57,60,66,86-87] screening and treatment of pregnant women for sexually transmitted 
infection during the antenatal period [6,18,24,56,72-74,82-83], and preventive measures against 
the spread of sexually transmitted infection [18,72-74,82]. Treatment of ophthalmia neonatorum 
involves the use of anti-infective agents to eliminate the condition in the neonate [6,12-13,18,57-
58,87-88]. 
1.5.1 Use of prophylaxis to prevent ophthalmia neonatorum 
The practice of eye prophylaxis at birth involves cleaning the eyes of the neonate before 
administering a safe anti-infective agent into the eye, which should reduce growth of ophthalmia 
neonatorum causing organisms. Historically, prophylaxis for ophthalmia neonatorum began with 
Carl Siegmund Franz Credé, a German obstetrician who  reduced the high incidence of ophthalmia 
neonatorum in babies born to mothers in his hospital from 13.6% to 0.05% in 1881 through 
instillation of silver nitrate into the eyes of the newborns at birth [28]. A similar reduction in the 
incidence of ophthalmia neonatorum also occurred in Europe and other parts of the world 
following the use of Credé’s prophylaxis [26-27,30]. However, chemical conjunctivitis, 
inflammation of the eyes, and redness were observed in up to 91% of cases, although this resolved 
within 24-48 hours [6,30,65,89]. With the arrival of the antibiotic era and discovery that silver 
nitrate was ineffective against chlamydial ophthalmia neonatorum [18,57,88], its use has been 
largely abandoned [30]. 
Alternative prophylactic agents that have been used include penicillin, erythromycin, 
tetracycline, povidone iodine, gentamicin, neomycin, and chloramphenicol [87,89-90]. The World 
Health Organisation (WHO) [91], CDC [92], American College of Obstetricians and Gynecologists 
(ACOG), and American Academy of Pediatrics (AAP) [57], strongly favour the practice of ocular 
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prophylaxis for preventing gonococcal conjunctivitis in all neonates. Additionally, the WHO 
supports ocular prophylaxis for chlamydial conjunctivitis in newborns and conditionally 
recommends using prophylactic agents like 0.5% erythromycin eye ointment, 1% tetracycline 
hydrochloride eye ointment, 2.5% povidone iodine, 1% silver nitrate solution, and 1% 
chloramphenicol eye ointment, depending on cost and local resistance to the prophylactic agents 
[88,91,93]. The CDC, however, does not recommend silver nitrate, tetracycline, gentamicin, 
bacitracin, or povidone iodine, but favours 0.5% erythromycin as ocular prophylaxis for 
ophthalmia neonatorum [57,92].  
Different studies have suggested that the effectiveness of these prophylactic agents 
against ophthalmia neonatorum varies when they are compared together. In a 1947 study, 
benzylpenicillin (2,500 units/ml) was administered topically once a day for three days, 
demonstrating good results with less irritation compared to silver nitrate [94]. However, it is not 
effective against C. trachomatis and may instead contribute to persistence of chlamydial infection 
[95]. This limitation, the prevalence of penicillin resistance in N. gonorrhoeae currently [96], and 
the need for dose administration over several days, makes it suboptimal as a prophylaxis for 
ophthalmia neonatorum. 
There are limitations for each of the prophylaxis agents 1% (w/v) silver nitrate, 1% (w/v) 
tetracycline ointment, and 0.5% (w/v) erythromycin ointment (Table 1). Silver nitrate is 
inexpensive, but due to issues with toxicity and chemical conjunctivitis has fallen out of favour 
and has been discontinued in many parts of the world [30]. Additionally, prophylaxis failures with 
silver nitrate still require treatment. By comparison, tetracycline is non-toxic, readily available in 
many developing countries, and the ointment is effective against N. gonorrhoeae, provided it is 
not resistant to tetracycline [24,30] However, routine tetracycline ocular prophylaxis is 
ineffective against chlamydial infection, which could subsequently result in respiratory infection 
in the infant. Erythromycin is considered ineffective for treatment of gonococcal STIs, thus the 
WHO recommended use of azithromycin in dual therapy [91]. Azithromycin is not, however, 
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available for ocular application. Erythromycin prophylaxis for ophthalmia neonatorum is 
recommended in many countries and is effective against C. trachomatis and possibly some 
sensitive isolates of N. gonorrhoeae and other infectious agents. Unfortunately, it is often not 
available in many lower income countries, due to the cost of erythromycin ointment [24,88,91]. 
Although prophylactic use of erythromycin has been linked with the occurrence of infantile 
hypertrophic pyloric stenosis, a condition that causes chronic vomiting in infants [98], the United 
States Preventative Serves Task Force (USPTF) recommends 0.5% erythromycin ophthalmic 
ointment prophylaxis in neonates [57]. 
Povidone iodine has been reported to possess antibacterial and antiviral properties, 
better efficacy, less toxicity, and less antimicrobial resistance than silver nitrate, tetracycline, and 
erythromycin [24,32,99]. The effectiveness of povidone iodine was also shown in some cases to 
be comparable with chloramphenicol for prophylaxis against ophthalmia neonatorum [101-102] 
and to have antiviral activity against herpes simplex virus and human immunodeficiency virus 
[30,95]. The minimal toxicity exhibited by 2.5% (w/v) povidone iodine is within neonatal 
tolerable limits [29,95], however this becomes a cause for concern with higher 5% (w/v) 
povidone iodine concentrations or more [29,103]. A study that observed a higher toxicity rate for 
povidone iodine 2.5% when compared to tetracycline, also noted that the rates were still lower 
than was previously reported [86]. According to the CDC, povidone iodine use has not been 
sufficiently studied [92] and a risk of harm may result because of the likely confusion with the 
well-known detergent formulation [56,87,91-92].  
Gentamicin was previously recommended as an alternative ocular prophylaxis, due to 
shortages in availability of erythromycin ointment. Gentamicin is no longer recommended for 
neonatal application because of severe reactions, such as lid swelling and dermatitis associated 
with its use [18,92]. 
 
1.5.2 Treatment of ophthalmia neonatorum with anti-infective agents 
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After the establishment of infection, anti-infective agents must be used to treat 
ophthalmia neonatorum to eliminate the bacteria and potential damage to the eye resulting from 
untreated infection. Systemic treatment, in addition to topical treatment, is helpful in stopping 
the spread of the infectious agent causing ophthalmia neonatorum to other parts of the body 
[6,87-88,91-93]. The sole use of topical ocular agents may not be sufficient and in some cases may 
not be used in favour of systemic treatment [92]. Treatment should be guided by the causative 
agent that is involved. After diagnosis, treatment for chlamydial conjunctivitis involves 
administration of a daily dose of 50 mg/kg of oral erythromycin in four divided doses for two 
weeks [92,104]. As an alternative, the CDC recommends a daily dose of 20 mg/kg azithromycin 
suspension administered orally for three days [92]. Azithromycin, at this dosage, is the standard 
recommendation from the WHO, over erythromycin because of the potential risk of infantile 
hypertrophic pyloric stenosis with erythromycin [98]. There is consensus, however, that the 
infant should be monitored for side effects with either medication [91-92]. 
Treatment for neonatal gonococcal conjunctivitis recommended by the CDC involves a 
single dose of 25-50 mg/kg (125 mg maximum) ceftriaxone given intravenously or 
intramuscularly [92]. This regimen is also advocated for neonates without signs of infection that 
are born to mothers infected with untreated N. gonorrhoeae [92]. The WHO recommends 
treatment of gonococcal ophthalmia neonatorum with a single dose of ceftriaxone 50 mg/kg 
(maximum 150 mg) given intramuscularly, or a single dose of kanamycin 25 mg/kg (maximum 
75 mg) given intramuscularly, or a single dose of spectinomycin 25 mg/kg (maximum 75 mg) 
administered intramuscularly [91]. 
1.5.3 Screening and treatment of pregnant women 
Since ophthalmia neonatorum is associated with sexually transmitted infections in the 
mother, screening of pregnant women for STIs during the antenatal stage of pregnancy has been 
advocated in some developed countries such as Canada [18], the USA [92], and Australia [105]. 
Following screening, mothers positive for STIs receive treatment for the infection rather than 
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subjecting the neonate to prophylaxis at birth. Screening of pregnant women may also help 
identify their sexual partners, diminish transmission, and decrease adverse pregnancy outcomes 
such as low birth weight [106], premature birth, premature rupture of the membranes 
surrounding the baby, pre-term labour, and miscarriage [107-108]. Screening and treatment of 
pregnant mothers has been found to be equally as effective in reducing the incidence of 
ophthalmia neonatorum in neonates [83] as prophylaxis of the infants at birth. Cost analysis has 
shown that as the prevalence of infections such as C. trachomatis increase in a population, there 
is an increase in the cost-effectiveness of screening all women compared to not screening or 
selectively screening, particularly in settings where resources for laboratory testing is already in 
place [56,105]. Modelling from The Netherlands of screening for C. trachomatis has demonstrated 
cost-effectiveness in screening all women. This model took a broad, yet conservative, view of 
whole health costs for treatment of infants and mothers if they were not identified in screening, 
rather than just comparing the cost of screening versus cost of prophylaxis [109]. 
Implementation of a screening and treatment strategy in resource limited areas would 
require a point of care solution. One potential is the Cepheid GeneXpert C. trachomatis / N. 
gonorrhoeae (CT/NG) assay, which has been successfully used in indigenous communities in 
Australia [110-111] and Papua New Guinea [112]. Such successes for this fully automated 
molecular test in high burden, low resource settings demonstrate the feasibility of application of 
point of care testing to a screening and treatment strategy, provided appropriate treatments are 
available locally. The GeneXpert assay has similar accuracy as NAATs, however in this assay the 
reagents come in disposable cartridges and results are available in 90 minutes, facilitating 
prompt management of infection treatment [111-112]. In comparison, NAATs results are 
available after 24 to 72 hours, necessitating a second visit to the clinic for patients to obtain 
treatment once a positive test result is obtained [82]. In remote communities, where greater 
commuting may be required for patients to reach test sites, there may be longer delays [113]. For 
this reason, point of care and rapid tests that are easy to use and provide a diagnosis while 
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patients wait may provide the needed solution to increasing the strategy of screening and 
treatment as a means to reduce ophthalmia neonatorum worldwide [110,114].  
Test of cure in the mothers has also been recommended to detect treatment failure if STI 
symptoms persist, if re-infection from the partner is suspected, or if therapeutic adherence is in 
doubt [92]. 
 
2.0 Challenges in preventing ophthalmia neonatorum 
2.1 The question of prophylaxis 
Despite the merits of the various strategies employed in managing ophthalmia 
neonatorum, there are certain inherent limitations. There are differences of opinion regarding 
the advantages of prophylactic treatment over non-use of prophylaxis [86,97,99,115-116]. Some 
studies show that ocular prophylaxis is clearly advantageous. However, in some areas, including 
Taiwan and Iran, current prophylaxis regimens (erythromycin, tetracycline, silver nitrate) are 
becoming ineffective, such that similar incidences of ophthalmia neonatorum occur with and 
without prophylaxis [116-117]. This may be due to the etiological agents. For example, a 2007 
study of the causative bacteria of cases in Iran identified, from most to least commonly isolated, 
coagulase-negative staphylococci, Gram-negative bacilli, Gram-positive bacilli, Escherichia coli, 
enterobacter, and coagulase-positive staphylococci [117]. Despite this evidence that current 
prophylaxis is not able to completely prevent ophthalmia neonatorum in some regions, there are 
numerous examples in the literature of hospitals returning to prophylaxis after a brief hiatus, 
making it clear that the prophylaxis has had a positive, real-world impact [118-119] and with the 
right new prophylaxis, which is effective against the disease causing agents, could do so again.  
As an historic example of the benefits of prophylaxis, silver nitrate use was discontinued 
for six months in 1957, at a hospital in New York (USA), during which time there were four cases 
of gonococcal ophthalmia neonatorum compared to a total of ten cases in the previous 25 years. 
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Silver nitrate prophylaxis was re-instated in the hospital [119].  In 1977, a similar reservation 
about chemical conjunctivitis led to a brief suspension of prophylactic use of silver nitrate 
solution in a maternity ward of a hospital in the United Republic of Cameroun. During an eight-
week period, 14% of women included in the study were culture positive for N. gonorrhoeae. These 
mothers gave birth to 12 infants with eyes that were culture positive for N. gonorrhoeae at 
delivery. Of these, four received silver nitrate prophylaxis and did not develop ophthalmia 
neonatorum. Of the remaining eight, seven returned in three days with purulent conjunctivitis 
and received treatment; the eighth did not return for follow-up [118]. As reported in 1984, a 
hospital in Nairobi, Kenya had discontinued ocular prophylaxis for six months and observed that 
23% of infants developed ophthalmia neonatorum, with 31% caused by C. trachomatis, 12% by 
N. gonorrhoeae, and 3% by both [120]. These cases led to a call to reintroduce ocular prophylaxis 
[12]. Prophylaxis to prevent ophthalmia neonatorum continues in countries including Spain 
[121], Brazil [122], the United States of America [57], Slovenia [123], Croatia [9], Canada [18], 
France [124], and Tanzania [125] (Table 2). However, prophylaxis has been discontinued in other 
countries, where the incidence of STIs is believed to be lower and where ophthalmia neonatorum 
risk is believed to therefore be lower, such as in Australia [126], United Kingdom [72], The 
Netherlands [109], Sweden [30], Denmark [30], and Belgium [127] (Table 2). In such countries, 
mothers may be screened or assessed for risk of STI prior to giving birth.   
 
2.2 Multi-drug resistant N. gonorrhoeae 
Despite over 100 years of medical intervention to prevent ophthalmia neonatorum from 
causing permanent ocular damage and blindness, it is still a concern today. Blindness can still 
result from treatment failures due to delayed or incorrect treatments, particularly in the face of 
extensively antibiotic resistant N. gonorrhoeae [75-77], or in regions of the world where 
treatment is not available. N. gonorrhoeae was designated as a high priority pathogen in the 
antibiotic-resistant bacteria global priority list of the World Health Organization in 2017 [128]. 
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N. gonorrhoeae has shown resistance to all known antibiotic agents used for its treatment, making 
this etiological agent the single biggest challenge in treating ophthalmia neonatorum. 
In some regions, due to availability, cost, or shortages, the only available drug for either 
prophylaxis or treatment may be penicillin [129-130]. It was the first antibiotic to treat 
gonococcal eye infections. In 1930, a crude extract of Penicillium notatum cured gonococcal 
ophthalmia neonatorum [131]. However, many gonococci today are resistant to penicillin [96]. 
Tetracycline ointments and ophthalmic solutions have also been used worldwide to 
prevent ophthalmia neonatorum [86,116,132-133]. According to the CDC advice in 1966, 1% 
(w/v) tetracycline ointment provided effective prophylaxis against both gonococcal and 
chlamydial conjunctivitis when given once soon after birth [133]. However, in 1985, tetracycline 
resistant strains of N. gonorrhoeae emerged, and tetracycline was thereafter no longer 
recommended as a first line treatment [134-135]. Today, many N. gonorrhoeae are also resistant 
to tetracycline [135]. 
Erythromycin ointment (0.5% w/v) is recommended in the US for prophylaxis of 
gonococcal eye infections [57], despite the emergence of resistance to erythromycin in the late 
1970’s [135-136]. The ineffectiveness of erythromycin against gonorrhoea STIs [136-137] and 
subsequent recommendations by the WHO and CDC to use azithromycin means that resistance 
data for erythromycin is not generally collected, but what has been assessed historically was high, 
necessitating the cessation of use of erythromycin against gonococcal STIs [91-92]. 
The current internationally recommended treatment for gonorrhoea in the reproductive 
tract is a dual therapy with azithromycin (1-2 g) and ceftriaxone (250-500 mg). N. gonorrhoeae 
resistance to ceftriaxone has been observed in several countries including Austria, England, 
France, Japan, Norway, Slovenia, Spain, and Sweden, [138-141] with rising resistance figures 
world-wide [149-141]. The rise in gonorrhoea cases that are nearly impossible to treat due to 
high level resistance to both azithromycin and ceftriaxone [75-76], will inevitably lead to difficult 
and potentially impossible to treat cases of ophthalmia neonatorum. From a global public health 
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point of view, a new therapeutic compound or antimicrobial agent is essential for effective control 
of infectious ophthalmia neonatorum. 
Apart from antimicrobial resistance, cost and access to current antibiotics remain a 
challenge in treating ophthalmia neonatorum [30]. There is therefore the need to identify cost 
effective, potent, and accessible therapeutic agents for prophylaxis and treatment of ophthalmia 
neonatorum, to which the bacteria are unlikely to develop resistance. 
 
2.3 Challenges of screening during pregnancy 
Screening of pregnant women for sexually transmitted infection based on sexual history, 
behaviour, and screening tests, even though beneficial in managing ophthalmia neonatorum 
[6,18,24,56,72-74,82-83,92,105] may result in missed cases because of the asymptomatic nature 
of these infections. The high cost of screening and treating pregnant women, the possibility of 
reinfection, and inadequacy of health care in certain regions may make this option not viable 
[30,87-88,142]. Socially vulnerable women may not be able to access prenatal screening; it is 
believed that they are less apt to utilise prenatal care [143]. Apprehension about potentially 
testing positive for sexually transmitted diseases, including the possibility of false positive test 
results, may create panic and cause women not to attend clinics for prenatal care [143-145]. 
Alternative strategies involving antimicrobial treatment of all expectant mothers for infections 
may expose uninfected mothers to unwanted side effects of the medications [143].  
With a prenatal screening strategy alone, cases will be missed, and infants will develop 
ophthalmia neonatorum requiring treatment. If the infecting organism is a multi-drug resistant 
N. gonorrhoeae, where the disease progresses rapidly, and the treatment options are limited or 
may not exist locally, infants may be left with permanent loss of visual acuity or blindness. As 





3.0. Innovative potential prophylaxis and treatment options for ophthalmia neonatorum 
Fatty acids and their derivatives have been demonstrated to possess antimicrobial 
properties [146] that show promise as alternative prophylaxis and treatment regimens for 
ophthalmia neonatorum [146-149]. These antimicrobial agents occur abundantly in the natural 
environment making the potential for development of them into inexpensive therapies attractive, 
particularly in developing countries [146-151]. Monocaprin, myristoleic acid, palmitoleic acid, 
and linolenic acid have been demonstrated to rapidly kill N. gonorrhoeae in artificial tear fluid, 
eliminating all bacteria within 2 minutes [146]. N. gonorrhoeae did not develop resistance to 
monocaprin even when repeatedly passaged on media containing sublethal concentrations of this 
antimicrobial monoglyceride, nor did mutations accumulate in the genome indicative of the 
evolution of resistance [152]. In addition, monocaprin exhibits broad spectrum bactericidal 
activity against C. trachomatis [150-151], N. meningitidis, S. aureus, and P. aeruginosa [148]. This 
is especially important in cases where it may not be possible to readily differentiate the causative 
organism because of similarities in clinical manifestation and potential complications that may 
arise from instances of co-infection. Most importantly, these fatty acids and their derivatives have 
been demonstrated to be non-irritating in three separate ocular irritation assays [146]. 
Monocaprin has been shown to be effective at killing N. gonorrhoeae infecting primary human 
corneal cells in co-culture and to be able to clear bacteria infecting the surface of an explanted 
bovine eye [146]. With rapid antimicrobial activity, lack of irritation, and absence of resistance, 
fatty acids and their derivatives are promising as either a prophylaxis to prevent infection or a 
treatment to eliminate established bacterial infections caused by a range of species. 
There have also been investigations into antimicrobial natural products, which may 
address the challenges of prophylaxis and treatment of ophthalmia neonatorum, including those 
from traditional medicine and antimicrobial natural products. Antimicrobial activity has been 
demonstrated for mixed preparations based on a medieval treatment called ‘Bald’s Eye Salve’, 
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This contains allium species, garlic and leek or onions, mixed with wine and oxgall, left to react in 
a dark brass vessel for nine days [153-154]. Laboratory-generated mixtures, based on the 
medieval recipe demonstrated bactericidal activity against S. aureus, even in biofilms, [153-154], 
with the highest antimicrobial activity observed from the combination of ingredients specified in 
Bald’s Leechbook [153]. Although modern irritation studies have not yet been conducted, the 
historic document indicates that this preparation should be administered to the eyes of the 
patient [153]. Datamining of medieval texts is yielding information about additional recipes with 
promising antimicrobial properties, including those cited in these texts as being treatments for 
diseases of the eyes [155]. 
Essential oils extracted from plants like the Syzygium aromaticum flower (clove) have 
potent antibacterial activity and are therefore attractive as potential therapeutic agent to treat S. 
aureus bacterial infections of the eye [156]. The antimicrobial activity of eyebright, Euphrasia 
rostkoviana Hayne (Scrophylariaceae), has been demonstrated against S. aureus, S. epidermidis, 
Enterococcus faecalis, Escherichia coli, and Klebsiella pneumoniae [157] and some small-scale 
studies have investigated their use for conjunctivitis [158]. Bactericidal activity has been 
demonstrated for Melaleuca alternifolia essential oil against S. aureus, suggesting its potential use 
as a topical agent [159]. Due to the potential for essential oils to cause irritation, additional 
research and safety testing is needed before these could be considered as viable options. 
 
4.0 Conclusions 
Ophthalmia neonatorum remains a global concern and there is need for global action to 
revise the recommendations for prophylaxis and treatment options in the face of evolving 
resistance in N. gonorrhoeae. There are many challenges involved with ophthalmia neonatorum 
prophylaxis and treatment including chemical conjunctivitis, resistance to both topical and 
systemic antibiotics, inadequate access to medications due to cost, absence of screening during 
pregnancy, and lack of treatment for sexually transmitted infections in pregnant women in 
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developing countries. Despite these challenges, interventions such as fatty acids, natural 
products, and essential oils may be formidable treatment and prophylaxis regimens suitable for 
development into future clinical applications to protect infant sight. 
 
5.0. Expert commentary 
There are currently no universal guidelines regarding prophylaxis or treatment for 
ophthalmia neonatorum, largely due to vast differences in the prevalence of infectious agents 
within the population and availability of healthcare for pregnancy risk assessment, screening, 
treatment, infant prophylaxis, and infant treatment. Compounding these issues are rising rates of 
sexually transmitted infections worldwide, including in developed countries and the increasing 
reports of N. gonorrhoeae that are resistant to last-line antibiotics [74-79]. 
Whilst the treatment recommendations for reproductive tract N. gonorrhoeae infections 
have changed several times over the last few years to address the growing threat of extensively 
drug resistant gonorrhoea, there has been little change in treatment recommendations for 
ophthalmia neonatorum. The shortcomings of guidance in the light of N. gonorrhoeae resistance, 
the clinical consequences of corneal perforation, and the need for prompt treatment and follow-
up has been highlighted by clinicians [160]. The CDC recommendation for adult cases of 
gonococcal conjunctivitis is both a single 1 g dose of ceftriaxone given intramuscularly and a 
single 1 g oral dose of azithromycin [92], however this is theoretical and consultation with an 
infectious-disease specialist is recommended. When these antibiotics are ineffective, as in a case 
of gonococcal STI in 2018 [75], it is unclear what treatment options remain. Silver nitrate was 
highly effective in the past at preventing ophthalmia neonatorum, but it is clear that even if we 
are willing to accept the risk of chemical conjunctivitis and toxicity as have clinicians of the past 
[161], it was never effective in treatment of established infections. In 10-17% of infants receiving 
silver nitrate prophylaxis, ophthalmia neonatorum still developed [162] requiring treatment, 
which may not be possible if the bacteria are fully resistant to antibiotics. 
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Even in the United States and Canada there is inequality in access to prenatal care, which 
impacts the success of screening and treatment strategies for prevention of ophthalmia 
neonatorum [18,57]. For this reason, prophylaxis is still recommended in the US [57]. In addition, 
the average cost per infant for neonatal ocular prophylaxis with erythromycin is US$1.94 [163], 
while the cost of prenatal screening is US$13-US$20 [56,109]. There is therefore a cost advantage 
to prophylaxis compared to screening. 
Increases in antibiotic resistant gonococci and other non-STI ophthalmia neonatorum 
species mean that it is imperative that alternative ocular therapies are investigated, such as the 
fatty acid containing eye drops [146,148,150], the Medieval manuscript inspired remedies  [153],  
and other antimicrobials such as essential oils [156-159] that may be able to be used as readily 
accessible and inexpensive prophylaxis and as treatments for when prophylaxis fails or has not 
been administered. Options for treatment will also be important in cases of adult infections 
[2,50,160,164]. 
In addition to novel medical interventions, to meet the challenge of ophthalmia 
neonatorum, the issues surrounding stigma and shame associated with STIs must not be ignored. 
Even in regions with good access to healthcare and resources, patients avoid screening because 
of the stigma and shame implied by having an STI in many cultures [144,165-166]. Addressing 
the stigma of sexually transmitted diseases will require a partnership between stakeholders such 
as the WHO, governmental, and non-governmental organisations as well as multi-disciplinary 
collaborations with doctors, nurses, scientists, paediatricians, gynaecologists, optometrists, 
ophthalmologists, and primary health care workers. Working with local communities and being 
sensitive to cultures, it may be possible to reduce the stigma around STIs, increase the availability 
of testing for women, make treatment more accessible, and therefore reduce the risk of mothers 
transmitting sight-threatening infections to infants at birth. 
 
6.0. Five-year view  
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The identification of novel antimicrobial agents for prophylaxis and treatment of 
ophthalmia neonatorum that are inexpensive, have broad spectrum activity, cause less toxicity, 
do not generate ocular irritation, to which there is no resistance, and which are readily available 
for use in local communities, looks promising in meeting the challenge of ophthalmia 
neonatorum. If adequate funding is made available to research into fatty acids, natural products, 
historical remedies, and essential oils as options for ophthalmia neonatorum it may be possible 
to significantly reduce preventable blindness from infectious diseases, a major cause of infant 
blindness world-wide. This would make an important impact upon the quality of life for these 
individuals and their families, as well as their communities as a whole. Within five years it may 
be possible, given the current state of research in the area, to advance this work to the stage where 
these novel agents have been assessed in clinical trials and perhaps be in use as a standard 
therapy for universal prophylaxis and treatment of ophthalmia neonatorum. 
 
7.0. Key issues 
• Sexually transmitted infections are on the increase around the world, which will 
contribute to an increase in cases of ophthalmia neonatorum. 
• The most common causes of ophthalmia neonatorum are Chlamydia trachomatis and 
Neisseria gonorrhoeae, passed to the infant at birth from a mother who may be 
asymptomatic and unaware of her infection. 
• Ophthalmia neonatorum can lead to loss of visual acuity and even blindness within days 
of birth, particularly when caused by N. gonorrhoeae, where the disease progresses 
rapidly. 
• Prevention of ophthalmia neonatorum induced visual impairment can be achieved by 




• To prevent transmission of ocular infection causing bacteria to the infant, pregnant 
women must receive adequate health care, including screening and risk assessment for 
sexually transmitted infections, treatment for infection, and test of cure. 
• Prophylaxis with an antimicrobial agent applied to the ocular surface shortly after birth 
is intended to prevent the growth of bacteria that may have been transferred from mother 
to child during passage through the birth canal. 
• Not all mothers receive pre-delivery assessments and not all infants receive prophylaxis 
and even amongst those that do, some infants develop ophthalmia neonatorum requiring 
treatment. 
• Treatment for ophthalmia neonatorum has become more challenging due to increasing 
resistance to antibiotics, particularly in the case of N. gonorrhoeae. 
• Research and investment into innovative non-antibiotic agents for prophylaxis and 
treatment of ophthalmia neonatorum should be encouraged to replace or augment 
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Figure 1. Percentage of blindness and visual impairment due to ophthalmia neonatorum in parts 
of Asia and Africa. Countries and regions in Africa (top) and Asia (bottom) reporting cases of 
ophthalmia neonatorum as one of the causes of vision loss in populations of visually impaired or 











Table 1: Comparison of different prophylactic agents for ophthalmia neonatoruma 




Study Sizec Reference 




Erythromycin ointment was found 
to be more effective against 
chlamydial ophthalmia 
neonatorum than 1% silver nitrate 
Seattle, 
USA 
RCT 60 [97] 
Tetracycline vs Silver nitrate  
 
 
Silver nitrate (1%) was as effective 
as 1% (w/v) tetracycline ointment 
against ophthalmia neonatorum 
Zaire, DR 
Congo 
Quasi RCT 450 [167] 
Tetracycline vs Silver nitrate  
 
 
The effectiveness of 1% 
tetracycline is comparable with 





Quasi RCT 2732 [162] 
Erythromycin vs Silver 
nitrate  
Tetracycline vs Silver nitrate  
 
There was no significant difference 
in the effectiveness of 0.5% 
erythromycin or 1% tetracycline 
compared to silver nitrate in 










Tetracycline vs Silver nitrate  
 
Tetracycline drops performed 
better against chlamydial 
ophthalmia neonatorum than 
silver nitrate solution up to the 
14th day. Comparable results after 





Quasi RCT 900 [132] 
Silver nitrate vs No 
prophylaxis 
 
Tetracycline vs No 
prophylaxis 
 
Erythromycin vs No 
prophylaxis 
 
Erythromycin (0.5%; 1 or 2 doses) 
or 1% tetracycline or 1% silver 
nitrate did not greatly lower the 
incidence of chlamydial 
ophthalmia neonatorum when 
compared to no prophylaxis 
Taiwan, 
China 
Quasi RCT 4544 [116] 
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aStudies differed in diagnostic tests for detection of chlamydia. Pregnant women were only 
screened in two studies [97,168]. Efficacy against chlamydial ophthalmia neonatorum could not 
 
Povidone iodine vs Silver 
nitrate  
Erythromycin vs Silver 
nitrate  
Povidone iodine solution (2.5%) 
had greater efficacy against 
chlamydial ophthalmia 
neonatorum than 1% silver nitrate 
or 0.5% erythromycin ointment. 
Erythromycin performed better 
than silver nitrate. 
Kikuyu, 
kenya 
Quasi RCT 3117 [99] 
Chloramphenicol vs 
povidone iodine 
Povidone iodine (2.5%) was less 
effective than chloramphenicol for 
ophthalmia neonatorum due to 
chlamydia. 
Povidone iodine was associated 




Quasi RCT 2004f [101] 
Povidone iodine vs 
Erythromycin 
Povidone iodine (2.5%) 
significantly reduced incidence of 
ophthalmia neonatorum more 




RCT 310 [115] 
Povidone iodine vs 
Erythromycin 
Povidone iodine (2.5%) reduced 
incidence of ophthalmia 
neonatorum more than 0.5% 
(w/v) erythromycin ointment 
Tehran, 
Iran 
RCT 360 [100] 
Povidone iodine vs 
Tetracycline 
Tetracycline (1%) was slightly 
better than 2.5% povidone iodine 
against infective ophthalmia 
neonatorum and significantly 
better than povidone iodine 
against non-infective ophthalmia 
neonatorum. 
Povidone was linked with more 




RCT 410 [86] 
Chloramphenicol vs 
Povidone iodine 
The effectiveness of 2.5% 
povidone iodine was comparable 
to 1% chloramphenicol in reducing 
the bacteria colony forming units 
in ophthalmia neonatorum 
Jakarta, 
Indonesia 




be determined in three studies because no C. trachomatis were detected [86,102,167]. Efficacy 
against gonococcal ophthalmia neonatorum could not be determined in eight studies because no 
N. gonorrhoeae were detected [86,97,100-102,115-116,132]. 
bThe study design was RCT, a randomized control trial, or Quasi RCT, a quasi-randomized 
control trial. 
cThe study size indicates the number of subjects involved in the study. 
dC. trachomatis ophthalmia neonatorum 
eN. gonorrhoeae ophthalmia neonatorum 
fThere were a lot of babies lost to follow up in the study, which may have affected the sample 
size [101].  
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Table 2: Examples of countries that do and do not use prophylaxis for ophthalmia neonatorum 
Countries Practice of prophylaxisa Routine screening of 
pregnant womena,b 
References 
Australia No Yesc [126] 
Belgium No Yes [127] 
Brazil Yes No [122] 
Canada Yesd Yes [18] 
Croatia Yes No [9] 
Denmark No Yes [30] 
France Yes No [124] 
The Netherlands No Yes [109] 
Slovenia Yes No [123] 
Spain Yes Noe [121] 
Sweden No Yes [30] 
Tanzania Yes No [125] 
United Kingdom No Yes [72] 
United States Yes Yesb [57] 
aPrenatal screening may require access to healthcare and compliance by pregnant women 
whereas prophylaxis may be more accessible, if available. 
bIn some countries screening is only conducted on women deemed to be at risk of STI. 
cChlamydia (not gonorrhoeae testing) is part of routine prenatal screening. 
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dAlthough routine prenatal screening is practised in Canada, ocular prophylaxis is still used and 
even mandatory in some provinces. 
eChlamydia screening is not recommended for all pregnant women but is recommended for 
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